Abstract
Reduced coronary endothelium-dependent vasodilation may play a role in the pathophysiology of in-stent restenosis. Moreover, endothelial dysfunction may cause to progression of athetrosclerosis in coronary arteries in patients undergoing percutaneous coronary intervention, especially stent deployment. We believe that the agents improving endothelial dysfunction and healing-enhanced stents, namely vascular endothelial growth factor (VEGF)-eluting stents, estradiol-eluting stents and stents attracting endothelial cells, might take an important role in the prevention of stent restenosis strategies in the near future.
MeSH terms
-
Angioplasty, Balloon, Coronary / adverse effects
-
Angioplasty, Balloon, Coronary / methods*
-
Coronary Angiography
-
Coronary Restenosis / etiology
-
Coronary Restenosis / prevention & control*
-
Coronary Stenosis / diagnostic imaging
-
Coronary Stenosis / therapy*
-
Drug-Eluting Stents*
-
Endothelium, Vascular / drug effects*
-
Endothelium, Vascular / physiopathology
-
Estradiol / therapeutic use
-
Female
-
Humans
-
Male
-
Risk Assessment
-
Sensitivity and Specificity
-
Severity of Illness Index
-
Sirolimus / therapeutic use
-
Vascular Endothelial Growth Factors / therapeutic use
Substances
-
Vascular Endothelial Growth Factors
-
Estradiol
-
Sirolimus